查看購物車
  • English
  • Japanese
  • Korean
GM1神經節苷脂病治療市場規模、佔有率和成長分析：按療法、疾病、給藥途徑、應用、最終用戶、分銷管道和地區分類－2026-2033年產業預測
市場調查報告書
商品編碼
2091415

GM1神經節苷脂病治療市場規模、佔有率和成長分析：按療法、疾病、給藥途徑、應用、最終用戶、分銷管道和地區分類－2026-2033年產業預測

GM1 Gangliosidosis Treatment Market Size, Share, and Growth Analysis, By Treatment Type, By Disease Type, By Route of Administration, By Application, By End User, By Distribution Channel, By Region - Industry Forecast 2026-2033
出版日期: | 出版商: SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

2024 年全球 GM1 神經節苷脂病治療市場價值為 5.725 億美元，預計從 2025 年的 6.3605 億美元成長到 2033 年的 14.7639 億美元，預測期（2026-2033 年）的複合年成長率為 11.1%。

GM1神經節苷脂沉積症治療市場正在成長，其主要驅動力是有效療法的巨大未滿足需求。這種罕見的溶小體儲積症以BETA-半乳糖苷酶活性降低為特徵，雖然發生率低，但會導致嚴重的神經退化和高死亡率。孤兒藥的監管激勵措施確保了市場的穩定，而基因編輯技術的進步與支付方對創新療法的醫療覆蓋意願相契合，從而促進了產品的上市。近期一些臨床試驗，例如Orchard公司的GT-GM1試驗，證實了病患療效的改善，這進一步推動了醫保報銷，並吸引了創業投資用於擴大生產規模。此外，人工智慧（AI）正在透過簡化標靶發現、最佳化臨床試驗設計和提高患者招募效率來革新該領域，最終拓展了這一不斷發展的市場中可用的治療方法範圍。

全球GM1神經節苷脂沉積症治療市場按治療類型、疾病類型、給藥途徑、應用、最終用戶、分銷管道和地區進行細分。依治療類型分類，市場分為酵素替代療法（ERT）、基因療法、基材減少療法（SRT）和支持/症狀治療。依疾病類型分類，市場分為嬰兒型GM1神經節苷脂沉積症、青少年型GM1神經節苷脂沉積症及成人/晚髮型GM1神經節苷脂沉積症。依給藥途徑分類，市場分為靜脈注射、鞘內注射、口服和其他途徑。按應用分類，市場分為神經系統症狀管理、緩解疾病治療和支持性治療。依最終用戶分類，市場分為醫院、神經科專科中心、罕見疾病治療中心和研究機構。依分銷管道分類，市場分為醫院藥房、專科藥房和研究/臨床試驗管道。按地區分類，分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球GM1神經節苷脂病治療市場的成長要素

兒童神經科和代謝疾病專家的臨床意識不斷提高，對早期發現GM1神經節苷脂沉積症至關重要，從而能夠及時治療性介入。這種意識的增強促使相關人員預測患者數量將會增加，對已通過核准療法的需求也會不斷成長。此外，隨著認知度的提高，臨床醫師更傾向於將患者轉介至能夠提供先進治療的專科機構。這種轉診流程正在推動市場發展，並促進持續成長。因此，製藥公司正在優先研發緩解疾病藥物，醫療保健系統也將資源投入有效的治療方案中，最終促進市場更強勁且永續的擴張。

全球GM1神經節苷脂沉積症治療市場的限制因素

治療GM1神經節苷脂沉積症的高昂費用是阻礙治療方案廣泛普及的主要障礙。定價通常反映了複雜的生產流程和規模較小且特殊的患者群體。保險公司通常要求在批准承保前進行全面的衛生經濟評估，這導致許多尋求治療的患者延誤治療。這種經濟負擔可能會阻礙醫療服務提供者開立這些昂貴的處方，尤其是在預算緊張的地區。因此，市場滲透率仍然有限，迫使製藥公司在定價和可負擔性之間尋求微妙的平衡，以確保永續成長。此外，保險公司可能會設定使用限制，進一步縮小符合治療條件的患者族群。

GM1神經節苷脂沉積症治療的全球市場趨勢

基因療法的進步正推動全球GM1神經節苷脂沉積症治療市場發生重大模式轉移。病毒載體工程和基因組編輯平台的革新，透過提高標靶遞送至中樞神經系統的轉導效率並降低免疫抗原性，拓展了治療選擇。整合患者登記的合作臨床舉措正在完善給藥方案，並實現對治療結果的更有效追蹤。這一強勁勢頭正推動生技公司加大投資，並促進與大型製藥企業的合作，加速創新療法從早期發現階段邁向III期臨床試驗的進程。基因療法正逐漸成為該領域未來治療策略的基礎要素。

目錄

介紹

  • 調查目的
  • 市場定義和範圍

調查方法

  • 研究過程
  • 二級資料和一級資料的方法
  • 市場規模估算方法

執行摘要

  • 全球市場展望
  • 市場主要亮點
  • 細分市場概覽
  • 競爭環境概述

市場動態及展望

  • 總體經濟指標
  • 促進者和機會
  • 抑制因素和挑戰
  • 供給面趨勢
  • 需求面趨勢
  • 波特的分析和影響

關鍵市場分析

  • 關鍵成功因素
  • 影響市場的因素
  • 主要投資機會
  • 生態系測繪
  • 2025年市場魅力指數
  • PESTLE分析
  • 監理情勢
  • 疾病流行病學

全球GM1神經節苷脂病治療市場規模：依治療類型分類

  • 酵素替代療法（ERT）
  • 基因治療
  • 基材減少療法（SRT）
  • 支持性護理與症狀治療

全球GM1神經節苷脂病治療市場規模：依疾病類型分類

  • 嬰兒型GM1神經節苷脂病
  • 青少年GM1神經節苷脂病
  • 成人發病/遲發性GM1神經節苷脂病

全球GM1神經節苷脂病治療市場規模：依給藥途徑分類

  • 靜脈
  • 鞘內給藥
  • 口服
  • 其他

全球GM1神經節苷脂病治療市場規模：依應用分類

  • 神經系統症狀的管理
  • 緩解疾病治療
  • 支持性護理

全球GM1神經節苷脂病治療市場規模：依最終用戶分類

  • 醫院
  • 專科神經科中心
  • 罕見疾病治療中心
  • 研究機構

全球GM1神經節苷脂病治療市場規模：按分銷管道分類

  • 醫院藥房
  • 專科藥房
  • 研究和臨床試驗管道

全球GM1神經節苷脂病治療市場規模：按地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 西班牙
    • 法國
    • 英國
    • 義大利
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太國家
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲國家
  • 中東和非洲
    • 海灣合作理事會國家
    • 南非
    • 其他中東和非洲國家

競爭資訊

  • 前五大公司對比
  • 主要公司2025年的市場定位
  • 主要市場公司採取的策略
  • 近期市場趨勢
  • 企業市場占有率分析，2025 年
  • 主要公司的完整公司簡介
    • 公司詳情
    • 產品系列分析
    • 按細分市場進行企業市佔率分析
    • 銷售收入年比比較（2023-2025 年）

主要公司簡介

  • Passage Bio, Inc.
  • Sio Gene Therapies Inc.
  • Sangamo Therapeutics, Inc.
  • Abeona Therapeutics Inc.
  • Ultragenyx Pharmaceutical Inc.
  • Amicus Therapeutics, Inc.
  • REGENXBIO Inc.
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Denali Therapeutics Inc.
  • Orchard Therapeutics plc
  • Rocket Pharmaceuticals, Inc.
  • Neurogene Inc.
  • Avrobio, Inc.
  • Bluebird Bio, Inc.
  • Esteve Pharmaceuticals SA
  • Lysogene SA
  • uniQure NV
  • Forge Biologics, Inc.

結論與建議

簡介目錄
Product Code: SQMIG35I3050

Global Gm1 Gangliosidosis Treatment Market size was valued at USD 572.5 Million in 2024 and is poised to grow from USD 636.05 Million in 2025 to USD 1476.39 Million by 2033, growing at a CAGR of 11.1% during the forecast period (2026-2033).

The GM1 gangliosidosis treatment market is experiencing growth driven by a significant unmet medical need for effective therapies. This rare lysosomal storage disorder, characterized by reduced B-galactosidase activity, leads to severe neurological degeneration and high mortality rates despite its low prevalence. Regulatory incentives for orphan drugs provide stability to the market, while advancements in gene-editing technologies align with payer readiness to cover innovative therapies, facilitating smoother product launches. Recent clinical trials, like Orchard's GT-GM1 trial showing improvements in patient outcomes, further stimulate reimbursement efforts and attract venture capital for scaling manufacturing. Additionally, artificial intelligence is revolutionizing the landscape by streamlining target discovery, optimizing clinical trial design, and enhancing patient recruitment, ultimately expanding the treatment approaches available in this evolving market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gm1 Gangliosidosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gm1 Gangliosidosis Treatment Market Segments Analysis

The global GM1 gangliosidosis treatment market is segmented by treatment type, disease type, route of administration, application, end user, distribution channel and region. Based on treatment type, the market is segmented into Enzyme Replacement Therapy (ERT), Gene Therapy, Substrate Reduction Therapy (SRT) and Supportive & Symptomatic Care. Based on disease type, the market is segmented into Infantile GM1 Gangliosidosis, Juvenile GM1 Gangliosidosis and Adult/Late-Onset GM1 Gangliosidosis. Based on route of administration, the market is segmented into Intravenous, Intrathecal, Oral and Others. Based on application, the market is segmented into Neurological Symptom Management, Disease-Modifying Treatment and Supportive Care. Based on end user, the market is segmented into Hospitals, Specialty Neurology Centers, Rare Disease Treatment Centers and Research Institutes. Based on distribution channel, the market is segmented into Hospital Pharmacies, Specialty Pharmacies and Research & Clinical Trial Channels. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gm1 Gangliosidosis Treatment Market

Increased clinical awareness among pediatric neurologists and metabolic specialists plays a crucial role in the early identification of GM1 gangliosidosis, enabling timely therapeutic interventions. This enhanced recognition leads to a growing demand for approved treatments, as stakeholders anticipate a larger patient population. Furthermore, as awareness improves, clinicians are more inclined to refer patients to specialized centers where advanced therapies are accessible. This referral process fuels market momentum and contributes to continual growth. Consequently, pharmaceutical companies prioritize the development of disease-modifying agents, while healthcare systems allocate resources toward effective treatment pathways, ultimately fostering a more robust and sustainable market expansion.

Restraints in the Global Gm1 Gangliosidosis Treatment Market

The prohibitive cost of treatments for GM1 gangliosidosis poses a significant barrier to widespread adoption of available therapies. The pricing often reflects the intricate manufacturing processes and the small, specialized patient population. Insurers typically require comprehensive health economic evaluations prior to approving coverage, resulting in delays for many patients seeking treatment. This financial strain can cause providers to hesitate in prescribing these costly interventions, particularly in regions with budget limitations. Consequently, market penetration remains limited, compelling manufacturers to navigate a delicate balance between pricing and affordability to ensure sustained growth. Furthermore, insurers may impose restrictions on utilization, further narrowing the eligibility pool for prospective patients.

Market Trends of the Global Gm1 Gangliosidosis Treatment Market

The Global GM1 Gangliosidosis Treatment market is experiencing a significant paradigm shift driven by advancements in gene therapy. The evolution of viral vector engineering and genome editing platforms is enhancing therapeutic options, marked by improved transduction efficiency and reduced immunogenicity for targeted delivery to the central nervous system. Collaborative clinical initiatives incorporating patient registries are refining dosing protocols and tracking outcomes more effectively. This robust momentum is attracting a surge of investment from biotech firms and fostering partnerships with major pharmaceutical companies, accelerating the transition of innovative treatments from early-stage discovery to pivotal trials. Gene-based interventions are positioning themselves as fundamental components of future treatment strategies in this sector.

Table of Contents

Introduction

  • Objectives of the Study
  • Market Definition & Scope

Research Methodology

  • Research Process
  • Secondary & Primary Data Methods
  • Market Size Estimation Methods

Executive Summary

  • Global Market Outlook
  • Key Market Highlights
  • Segmental Overview
  • Competition Overview

Market Dynamics & Outlook

  • Macro-Economic Indicators
  • Drivers & Opportunities
  • Restraints & Challenges
  • Supply Side Trends
  • Demand Side Trends
  • Porters Analysis & Impact
    • Competitive Rivalry
    • Threat of Substitute
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Key Success Factors
  • Market Impacting Factors
  • Top Investment Pockets
  • Ecosystem Mapping
  • Market Attractiveness Index 2025
  • PESTEL Analysis
  • Regulatory Landscape
  • Disease Epidemiology

Global GM1 Gangliosidosis Treatment Market Size by Treatment Type & CAGR (2026-2033)

  • Market Overview
  • Enzyme Replacement Therapy (ERT)
  • Gene Therapy
  • Substrate Reduction Therapy (SRT)
  • Supportive & Symptomatic Care

Global GM1 Gangliosidosis Treatment Market Size by Disease Type & CAGR (2026-2033)

  • Market Overview
  • Infantile GM1 Gangliosidosis
  • Juvenile GM1 Gangliosidosis
  • Adult/Late-Onset GM1 Gangliosidosis

Global GM1 Gangliosidosis Treatment Market Size by Route of Administration & CAGR (2026-2033)

  • Market Overview
  • Intravenous
  • Intrathecal
  • Oral
  • Others

Global GM1 Gangliosidosis Treatment Market Size by Application & CAGR (2026-2033)

  • Market Overview
  • Neurological Symptom Management
  • Disease-Modifying Treatment
  • Supportive Care

Global GM1 Gangliosidosis Treatment Market Size by End User & CAGR (2026-2033)

  • Market Overview
  • Hospitals
  • Specialty Neurology Centers
  • Rare Disease Treatment Centers
  • Research Institutes

Global GM1 Gangliosidosis Treatment Market Size by Distribution Channel & CAGR (2026-2033)

  • Market Overview
  • Hospital Pharmacies
  • Specialty Pharmacies
  • Research & Clinical Trial Channels

Global GM1 Gangliosidosis Treatment Market Size & CAGR (2026-2033)

  • North America (Treatment Type, Disease Type, Route of Administration, Application, End User, Distribution Channel)
    • US
    • Canada
  • Europe (Treatment Type, Disease Type, Route of Administration, Application, End User, Distribution Channel)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Treatment Type, Disease Type, Route of Administration, Application, End User, Distribution Channel)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Treatment Type, Disease Type, Route of Administration, Application, End User, Distribution Channel)
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Treatment Type, Disease Type, Route of Administration, Application, End User, Distribution Channel)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2025
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2025
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

  • Passage Bio, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sio Gene Therapies Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sangamo Therapeutics, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Abeona Therapeutics Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ultragenyx Pharmaceutical Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Amicus Therapeutics, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • REGENXBIO Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceutical Company Limited
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Denali Therapeutics Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Orchard Therapeutics plc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Rocket Pharmaceuticals, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Neurogene Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Avrobio, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bluebird Bio, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Esteve Pharmaceuticals S.A.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Lysogene S.A.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • uniQure N.V.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Forge Biologics, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations